Singapore markets closed

Straits Times Index
3,332.80
-10.55(-0.32%)
Nikkei
39,583.08
+241.54(+0.61%)
Hang Seng
17,718.61
+2.14(+0.01%)
FTSE 100
8,164.12
-15.56(-0.19%)
Bitcoin USD
60,957.36
-314.55(-0.51%)
CMC Crypto 200
1,268.75
-15.08(-1.17%)

ITCI Jan 2025 40.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

30.00

0.00

(0.00%)

At close: 02:46PM EDT

Loading interactive chart…

Zacks
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Zacks
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Zacks
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.